Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Hits New 52-Week High – Here’s Why

Bayer Aktiengesellschaft (OTCMKTS:BAYRY)’s stock price reached a new 52-week high during mid-day trading on Monday . The company traded as high as $11.16 and last traded at $11.0875, with a volume of 111308 shares trading hands. The stock had previously closed at $11.09.

Wall Street Analyst Weigh In

Several brokerages have weighed in on BAYRY. Zacks Research downgraded Bayer Aktiengesellschaft from a “strong-buy” rating to a “hold” rating in a report on Monday, November 3rd. JPMorgan Chase & Co. raised Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a research report on Monday, December 8th. Finally, Morgan Stanley upgraded shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research note on Wednesday, December 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy”.

Bayer Aktiengesellschaft Price Performance

The stock has a market capitalization of $43.58 billion, a price-to-earnings ratio of -123.88, a price-to-earnings-growth ratio of 5.48 and a beta of 0.66. The company has a current ratio of 1.13, a quick ratio of 0.73 and a debt-to-equity ratio of 1.04. The company’s 50 day moving average is $9.21 and its 200 day moving average is $8.43.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.